New research
Treatment of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Irritability: Results From the Multimodal Treatment Study of Children With ADHD (MTA)

https://doi.org/10.1016/j.jaac.2014.10.006Get rights and content
Under a Creative Commons license
open access

Objective

Clinically impairing irritability affects 25% to 45% of children with attention-deficit/hyperactivity disorder (ADHD); yet, we know little about what interventions are effective in treating children with ADHD and co-occurring irritability. We used data from the Multimodal Treatment Study of Children With ADHD (MTA) to address 3 aims: to establish whether irritability in children with ADHD can be distinguished from other symptoms of oppositional defiant disorder (ODD); to examine whether ADHD treatment is effective in treating irritability; and to examine how irritability influences ADHD treatment outcomes.

Method

Secondary analyses of data from the MTA included multivariate analyses, and intent-to-treat random-effects regression models were used.

Results

Irritability was separable from other ODD symptoms. For treating irritability, systematic stimulant treatment was superior to behavioral management but not to routine community care; a combination of stimulants and behavioral treatment was superior to community care and to behavioral treatment alone, but not to medication alone. Irritability did not moderate the impact of treatment on parent- and teacher-reported ADHD symptoms in any of the 4 treatment groups.

Conclusion

Treatments targeting ADHD symptoms are helpful for improving irritability in children with ADHD. Moreover, irritability does not appear to influence the response to treatment of ADHD.

Clinical trial registration information

Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA); http://www.clinicaltrials.gov; NCT00000388.

Key Words

irritability
attention-deficit/hyperactivity disorder
oppositional defiant disorder
treatment outcomes

Cited by (0)

Clinical guidance is available at the end of this article.

Supplemental material cited in this article is available online.

Dr. Fernández de la Cruz was fully supported and Dr. Simonoff was partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust and the Institute of Psychiatry, King’s College London. The Multimodal Treatment Study of Children With ADHD (MTA) has been supported by the following grant numbers: U01MH50440, U01MH50447, U01MH50453, U01MH50454, U01MH50461, U01MH50467, and the following contract numbers: N01MH12004, N01MH12007, N01MH12008, N01MH12009, N01MH12010, N01MH12011, N01MH12012; HHSN271200800003-C, HHSN271200800004-C, HHSN271200800005-C, HHSN271200800006-C, HHSN271200800007-C, HHSN271200800008-C, and HHSN271200800009-C. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the Department of Health, the MTA Study Investigators, the National Institutes of Health (NIH), the NHS, or the NIHR.

John Hodsoll, PhD, of King’s College London served as the statistical expert for this research.

Disclosure: Dr. McGough has received grant or research support from NIH, NeuroSigma, Inc., Purdue Pharma L.P., and Shire Pharmaceuticals. He has served as a consultant to Akili Interactive Labs, Merck, Neurovance, and Sunovion. He has presented expert testimony for Shire. Dr. Arnold has received research funding from Curemark, Forest, Eli Lilly and Co., Neuropharm, Novartis, Noven, Shire, Young Living, NIH, and Autism Speaks, and has consulted with or been on advisory boards for Gowlings, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and Tris Pharma, and has received travel support from Noven. Dr. Stringaris has received grant or research support from the Wellcome Trust, the NIHR, and the Department of Health UK. He has received royalties from Cambridge University Press for his book The Maudsley Reader in Phenomenological Psychiatry. Drs. Fernández de la Cruz, Simonoff, and Halperin report no biomedical financial interests or potential conflicts of interest.